鼻咽癌放射治疗后99mTc-MIBI SPECT显像的临床价值

目的：评价^99mTc—MIBISPECT显像对鼻咽癌患者放疗后局部残余或复发病灶的鉴别价值。方法：48例经病理证实的原发性鼻咽癌患者于放疗后3个月行^99mTc—MIBISPECT显像,与同期的CT结果对照．并分别计算鼻咽部与头皮的放射性计数比值作为^99mTc—MIBI摄取指数（MUI）。以接受器工作特性曲线（ROC）分析确定MUI判别阈值。鼻咽内镜检查、病理活检及18个月的临床随访资料作为鼻咽癌病灶残余或鼻咽癌复发的依据。结果：以MUI≥1．33为阳性标准．^99mTc—MIBISPECT显像监测鼻咽癌病灶残余或复发的敏感度73．33％,特异度93．94％,诊断符合率87．50％。CT监测鼻咽癌病灶残余或复发的敏感度73．33％,特异度84．85％,诊断符合率81．25％。^99mTc—MIBISPECT显像与CT联合鉴别鼻咽癌病灶残余或复发的敏感度、特异度和诊断符合率分别为100%、96．55％和97．30％。结论：^99mTc—MIBISPECT显像对鼻咽癌患者放疗后局部残余或复发病灶的鉴别有一定价值;与CT联合可有效提高对放疗后鼻咽癌病灶残余或复发的早期诊断效能。     

99 Tcm-MIBI SPECT在原发性鼻咽癌诊断、放疗后残余或复发监测中的应用

目的：评价^99Tc^m-甲氧基异丁基异腈(MIBI)SPECT显像对原发性鼻咽癌的诊断和鼻咽癌放疗后局部残余或复发的鉴别价值。方法：20例经病理检查证实的原发性鼻咽癌患者于治疗前、放疗后3和6个月分别行^99Tc^m-MIBI SPECT显像，与同期CT和(或)MRI结果对照，分别计算肿瘤或正常鼻咽部与头皮的放射性计数比值，作为^99Tc^m-MIBI摄取指数(MUI)。以接受器工作特性(ROC)曲线确定MUI判别阈值。以鼻咽部内镜检查、病理活组织检查及18个月的临床随访资料作为鼻咽癌残余或复发的依据。结果以MUI≥2．15为阳性标准，^99Tc^m-MIBISPECT显像诊断原发性鼻咽癌的灵敏度、特异性和准确性均为95％。以MUI≥1．32为阳性标准，^99Tc^m-MIBI SPECT显像监测鼻咽癌残余或复发的灵敏度为3／4例，特异性93．8％，准确性90．0％。CT和(或)MRI监测鼻咽癌残余或复发的灵敏度为3／4例，特异性81．3％，准确性80．0％。^99Tc^m-MIBISPECT显像与CT和(或)MRI联合鉴别鼻咽癌残余或复发的灵敏度、特异性和准确性分别为2／2例、92．9％和93．8％。结论:^99Tc^m-MIBI SPECT显像对确定鼻咽癌原发灶范围有一定价值；与CT和(或)MRI联合，可提高对放疗后鼻咽癌残余或复发的早期诊断效能。     

头颈部肿瘤99mTc-MIBI阳性显像的临床研究

目的:探讨99mTc-MIBI亲肿瘤显像在头颈部肿瘤定性诊断中的应用价值。方法:91例临床初诊为头颈部肿瘤的患者和20例正常志愿者行早期和延迟99mTc-MIBI头颈部断层显像。结果:99mTc-MIBI早期/延迟显像诊断头颈部恶性肿瘤的总体敏感度、特异度、准确度及阳性预测值分别为78.7%/72.3%、72.1%/88.4%、75.6%/80.0%和75.5%/87.2%;鼻咽癌、非霍奇金淋巴瘤显像效果优于上颌窦癌9。9mTc-MIBI显像对于鼻咽癌复发/残留以及鼻腔非霍奇金淋巴瘤定性诊断价值明显优于CT和MRI。结论:99mTc-MIBI亲肿瘤显像在头颈部肿瘤的定性诊断中有较好的应用前景。     

单电子发射断层成像/CT同机图像融合诊断乳腺癌骨转移的临床研究

目的评价单电子发射断层成像(SPECT)/CT同机图像融合显像对全身骨显像难于确诊乳腺癌骨病灶的鉴别诊断价值。方法对单纯全身骨显像难于确诊的75例乳腺癌患者的153个病灶行局部SPECT/CT同机融合断层显像。以临床病理、磁共振成像(MRI)、CT、骨扫描复查或PET/CT检查为确诊依据,计算诊断符合率、灵敏度、特异度、阳性预测值及阴性预测值。结果单纯全身骨显像无法确诊的153个病灶,经SPECT/CT融合断层正确诊断的恶性病灶51个(33.3%),良性病灶89个(58.2%)。诊断符合率91.5%,灵敏度92.7%,特异度90.8%,阳性预测值85.0%,阴性预测值95.7%。结论 SPECT/CT同机图像融合显像能够对单独SPECT骨扫描难于确诊的病灶进行准确诊断,明显地提高了乳腺癌骨转移病灶的诊断准确性,在女性乳腺癌患者骨病灶的鉴别诊断中具有很高的临床应用价值。     

头颈部肿瘤99mTc-MIBI阳性显像的临床研究

目的：探讨^99mTc-MIBI亲肿瘤显像在头颈部肿瘤定性诊断中的应用价值。方法：91例临床初诊为头颈部肿瘤的患者和20例正常志愿者行早期和延迟99mTc-MIBI头颈部断层显像。结果：^99mTc-MIBI早期／延迟显像诊断头颈部恶性肿瘤的总体敏感度、特异度、准确度及阳性预测值分别为78．7％／72．3％、72．1％／88．4％、75．6％／80．0％和75．5％／87．2％；鼻咽癌、非霍奇金淋巴瘤显像效果优于上颌窦癌^99mTc-MIBI显像对于鼻咽癌复发／残留以及鼻腔非霍奇金淋巴瘤定性诊断价值明显优于CT和MRI。结论：^99mTc-MIBI亲肿瘤显像在头颈部肿瘤的定性诊断中有较好的应用前景。     

~(99m)Tc-MIBI双时相显像与SPECT/CT融合显像对原发性甲状旁腺功能亢进症的诊断价值

目的探讨~(99)mTc-甲氧基异丁基异腈(MIBI)双时相显像与SPECT/CT融合显像在原发性甲状旁腺功能亢进症(PHPT)病灶定位及定性的诊断价值。方法 20例PHPT患者均行~(99)mTc-MIBI双时像显像及SPECT/CT同机融合显像,显像结果与术后病理结果相比较,分析两种方法的灵敏度。结果 20例PHPT患者术后病理均确诊为PHPT(28个病灶),其中甲状旁腺腺瘤16例(21个病灶),甲状旁腺增生2例(5个病灶),异位甲状旁腺腺瘤1例(1个病灶),甲状旁腺癌术后淋巴结转移1例(1个病灶)。~(99)mTc-MIBI双时相显像与SPECT/CT同机融合显像敏感性分别为64.3%和85.7%,两种检查方法有显著性差异(P0.05)。结论~(99)mTc-MIBI SPECT/CT同机融合显像是诊断PHPT的有效方法,其临床价值高于~(99)mTc-MIBI双时像显像。     

SPECT/CT骨显像对SAPHO综合征的诊断价值

目的探讨SPECT/CT骨显像在滑膜炎、痤疮、脓疱病、骨肥厚、骨髓炎（SAPHO）综合征诊断中的临床价值。方法回顾性分析临床怀疑SAPHO综合征的11例患者的临床资料及SPECT/CT骨显像结果,所有患者均行99Tcm-MDP全身骨显像+局部断层显像及同机或异机CT扫描,获得SPECT全身骨显像和局部SPECT骨显像、CT显像、SPECT/CT融合显像图像。分析比较SPECT骨显像和SPECT/CT融合显像对SAPHO综合征诊断的准确率、灵敏度和特异度,组间准确率的比较采用χ2检验。结果11例临床怀疑SAPHO综合征患者中,9例经穿刺组织病理或随访病情最终转归而确诊,另外2例为转移瘤。其中,SPECT诊断6例,共发现41个病灶出现放射性浓聚;SPECT/CT诊断9例,共发现44个病灶。SPECT骨显像的灵敏度、特异度和准确率分别为66.7%（6/9）、50.0%（1/2）和63.6%（7/11）;SPECT/CT融合显像的灵敏度、特异度和准确率分别为100%（9/9）、50.0%（1/2）和90.9%（10/11）,SPECT/CT融合显像对SAPHO综合症诊断的准确率明显高于单纯的SPECT显像,且差异具有统计学意义（χ2=11.82,P < 0.05）。结论SPECT/CT的联合应用提高了对病灶解剖定位的准确率及骨显像特异度,可用于SAPHO综合征患者的病灶精准定位、早期诊断与鉴别诊断、更多隐匿病灶检出以及病灶代谢活性评价等,对SAPHO综合征的诊断有较高的临床价值。     

SPECT/CT融合显像对乳腺癌骨转移的诊断价值

目的 评价SPECT/CT融合显像对^99Tc^m-MDP全身骨显像难于确诊的乳腺癌骨病灶的鉴别诊断价值.方法 对^99Tc^m-MDP全身骨显像难于确诊的132例乳腺癌患者的210个病灶行局部SPECT/CT同机融合断层显像,以临床随访及病理检查获得最终诊断结果,计算SPECT/CT融合显像对骨转移灶的诊断准确率、灵敏度、特异度、阳性预测值及阴性预测值,并对比不同部位病灶的诊断准确率差异.结果 ①210个病灶经SPECT/CT融合断层显像正确诊断的恶性病灶82个（39.0％）,良性病灶112个（53.3％）,诊断准确率为92.4％（194/210）,灵敏度为94.3％,特异度为91.1％,阳性预测值为88.2％,阴性预测值为95.7％.②SPECT/CT同机融合断层显像对不同部位的病灶的诊断准确率不一致,脊椎的诊断准确率最高,为95.9％（94/97）,肋骨最低,为83.7％（36/43）,其差异有统计学意义（χ^2=7.81,P＜0.05）.结论 SPECT/CT同机融合显像能够对^99Tc^m-MDP全身骨显像难于确诊的病灶进行准确诊断,其对不同部位的病灶的诊断准确率有差异,脊椎的诊断准确率最高,肋骨最低.     

恶性肿瘤患者脊柱病变的SPECT/CT诊断价值

目的: 探讨99mTc-MDP SPECT/CT骨显像诊断恶性肿瘤患者脊柱病灶的价值.材料和方法: 回顾性分析72例恶性肿瘤患者113个脊柱放射性浓聚灶的全身骨平面像、局部SPECT与SPECT/CT融合图像的代谢及CT表现.结果: 113个脊柱病灶按颈椎、胸椎、腰椎、骶椎分布分别为12个、40个、52个、9个,最后诊断良性灶73个(64.6%),恶性灶40个(35.4%).平面像、SPECT、SPECT/CT诊断符合率分别为45.1%、83.2%、94.7%,差异显著(P＜0.001).结论: 99mTc-MDP SPECT/CT骨显像对恶性肿瘤患者脊柱病灶的诊断具有很高的价值.     

18F-FDGSPECT/CT显像在鼻咽癌治疗后EBV-DNA升高患者中的应用

目的:探讨18F-FDG SPECT/CT显像在检测鼻咽癌治疗后血清EBV-DNA升高患者,肿瘤复发和(或)转移病灶的价值.方法:鼻咽癌治疗后血清EBV-DNA升高患者45例,皆行全身18F-FDG SPECT/CT显像.所有图像经图像融合后,进行18F-FDG显像图像和CT图像帧对帧对比分析.肿瘤复发和(或)转移病灶根据病理检查结果、多种影像学诊断及临床随访而确诊.随访时间均＞6个月.采用SPSS 11.5软件进行统计学处理,进行x2检验.结果:45例患者中,明确诊断肿瘤复发和(或)转移者35例,单纯CT诊断肿瘤复发和(或)转移28例,其灵敏度为80.0％ (28/35);符合线路18F-FDG CT同机融合显像诊断肿瘤复发和(或)转移32例,灵敏度提高至91.4％ (32/35).结论:18F-FDG SPECT/CT在检测鼻咽癌治疗后EBV-DNA升高患者肿瘤复发和(或)转移病灶中有较好的应用价值.但角化型鼻咽癌可能出现假阴性.     

脑肿瘤SPECT阳性显像与CT影像的对照研究

目的 :探讨99mTc MIBISPECT与CT在脑肿瘤的影像特征及其应用价值。材料和方法 :对 5 0例脑肿瘤、10例脑内非肿瘤病变患者行99mTc MIBISPECT及CT扫描 ,对其影像特点进行分析比较。结果 :99mTc MIBISPECT术前诊断脑肿瘤的灵敏度、特异性和准确性分别为 96.9%、90 .0 %和 95 .2 % ,而CT分别为 90 .6%、80 .0 %和 88.1% ,两者均无显著性差异(P >0 .0 5 ) ;99mTc MIBISPECT诊断胶质瘤术后残留与复发的灵敏度、特异性和准确性均为 10 0 % ,而CT分别为 3 0 %、75 %和 5 0 % ,前者比后者高 (P <0 .0 1)。结论 :99mTc MIBISPECT在诊断胶质瘤术后残留与复发方面可作为CT的一种有效补充手段 ;二者结合 ,对确定脑肿瘤的诊断具有重要的应用价值。     

Delineation of Target Volume for Radiotherapy of High-Grade Gliomas by 99mTc-MIBI SPECT and MRI Fusion

BACKGROUND AND PURPOSE: Computed tomography (CT) and magnetic resonance imaging (MRI) are traditionally used for treatment planning of high-grade glioma. 99m Tc-methoxy-isobutyl-isonitrile (MIBI) single-photon emission computed tomography (SPECT) showed high sensitivity and specificity in literature series. In the present study, it was investigated how the information provided by 99m Tc-MIBI SPECT and MRI fusion could affect target delineation for radiotherapy of high-grade glioma. PATIENTS AND METHODS: 21 patients with high-grade glioma were studied by MRI and 99m Tc-MIBI SPECT imaging. The gross tumor volume (GTV) was outlined on MRI (MRI-GTV) and SPECT images (SPECT-GTV). Three additional volumes were analyzed: the (MRI+SPECT)-GTV representing the whole amount of MRI-GTV plus SPECT-GTV, the (MRI&SPECT)-GTV identified by the overlapping region of MRI-GTV and SPECT-GTV, and the (SPECT/MRI)-GTV identified by the extension of SPECT-GTV outside MRI-GTV. RESULTS: MRI contrast-enhanced and 99m Tc-MIBI SPECT-positive lesions were found in all 21 patients. The average SPECT-GTV was slightly larger than the average MRI-GTV, with greater difference for resected than for unresected cases. The average increment of (MRI+SPECT)-GTV compared to MRI-GTV was 33%, being significantly higher for resected than for unresected cases (p = 0.006). CONCLUSION: The fusion of 99m Tc-MIBI SPECT and MRI significantly affected the delineation of the target volume identified by MRI alone.     

Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile

The value of technetium-99m methoxy-isobutylisonitrile (MIBI) single-photon emission tomography (SPET) of the chest in differentiating lung carcinomas of various histological types and benign lesions was assessed in 54 patients (47 males and 7 females aged 19–77 years) with single solid lung masses. Chest radiography had indicated that 46 of the lesions were malignant (8 small cell carcinomas, 14 epidermoid carcinomas, 18 adenocarcinomas and 6 undifferentiated large cell carcinomas) and eight, benign. Ten, volunteers who also agreed to undergo ^99mTc-MIBI SPET of the chest served as a control group. The results showed that only 65% (30/46) of the lung malignancies were detected by ^99mTc-MIBI SPECT, including 63% (5/8) of the small cell carcinomas, 64% (9/14) of the epidermoid carcinomas, 72% (13/18) of the adenocarcinomas and 50% (3/6) of the undifferentiated large cell carcinomas. However, 75% (6/8) of the benign lesions were also detected. The diagnostic sensitivity, specificity and accuracy in differentiating malignant and benign lesions were 65%, 57% and 70%, respectively. We conclude that ^99mTc-MIBI is of limited use in the differentiation of single solid lesions in the lungs. Correspondence to: Chia-Hung Kao     

吸氧99Tcm-MIBI SPECT与定位CT结合对肺部病灶的鉴别诊断价值

目的 探讨吸氧99Tcm-甲氧基异丁基异腈（MIBI）SPECT与定位CT结合对肺部病灶的鉴别诊断价值,为肺部病灶的良恶性鉴别建立一种高性价比方法。方法对2008年9月至2009年3月47例可疑恶性肺部病灶患者进行前瞻性研究,对疑似炎性反应病例短期应用抗生素。所有受检者于注射99TcmMIBI前开始经鼻腔导管吸氧,注射后10min进行SPECT与CT定位融合显像,2h后进行延迟显像。对良、恶性肺部病灶（T）与对侧相应肺组织（N）的摄取比值（早期：EUR,延迟：DUR）比较应用独立样本t检验,并对EUR和DUR的诊断效率进行受试者工作特征（ROC）曲线分析。结果47例患者（32例原发性肺癌,4例肺转移,11例良性病变）共51个肺部病灶,恶性病灶39个,良性病灶12个。99TcmMIBISPECT与定位CT融合显像诊断肺部良恶性病灶的灵敏度、特异性、准确性、阳性预测值和阴性预测值分别为94．9％（37／39）、83．3％（10／12）、92．2％（47／51）、94．9％（37／39）和83．3％（10／12）。恶性病灶EUR为2．95±1．16[95％可信区间（CI）：2．57～3．32）],良性病灶EUR为1．43±0．33（95％CI：1．22～1．64）,两者差异有统计学意义（t=-4．44,P〈0．01）;恶性病灶DUR为3．19±1．74（95％CI：2．62—3．75）,良性病灶DUR为1．60±0．32（95％CI：1．39—1．81）,两者差异有统计学意义（t=-3．12,P〈0．01）。半定量ROC分析显示：以EUR≥1．625为诊断肺部恶性病灶的界值,灵敏度97．4％（38／39）,特异性83．3％（10／12）;以DUR≥1．75为诊断肺部恶性病灶的界值,灵敏度94．9％（37／39）,特异性83．3％（10／12）。结论吸氧99TcmMIBISPECT与定位CT结合显像对肺部病灶的良恶性鉴别具有较高的临床价值。     

Attenuation-corrected 99mTc-MIBI SPECT in overweight patients with chronic ischaemic dysfunction: a comparison to NH3 PET and implications for the diagnosis of myocardial viability

OBJECTIVE: We determined the value of attenuation correction (AC) of myocardial perfusion estimation with (99m)Tc-MIBI SPECT in overweight patients by comparison of uncorrected (filtered back-projection (FBP) and corrected (an iterative algorithm with a measured attenuation coefficients map (FL-AC)) (99m)Tc-MIBI relative uptake to perfusion data obtained in the same patients with NH3 PET. In addition, the impact of attenuation correction for the assessment of myocardial viability with (99m)Tc-MIBI SPECT was determined using FDG PET as the reference method. METHODS: Thirty consecutive overweight patients (BMI=28+/-4) with left ventricular dysfunction underwent a resting (99m)Tc-MIBI SPECT and a PET study (NH3 and FDG). (99m)Tc-MIBI SPECT scans were reconstructed without attenuation correction (FBP) and with attenuation correction (FL-AC). The left ventricle was divided into 16 segments, in which the relative uptake was quantified using circumferential profiles. A relative uptake > or = 60% was considered consistent with viable myocardium for FDG and MIBI. RESULTS: The absolute difference between (99m)Tc-MIBI SPECT and NH3 PET uptakes was less pronounced in the inferior (12+/-10% vs. 17+/-12%, P<0.001), anteroseptal (12+/-11% vs. 16+/-12%, P=0.009) and septal (15+/-12% vs. 18+/-14%, P=0.003) regions (FL-AC vs. FBP, respectively). The sensitivity of MIBI for diagnosing myocardial viability increased from 83 to 100% (P=0.034), without loss in specificity. CONCLUSION: Attenuation correction improves myocardial perfusion estimation by (99m)Tc-MIBI SPECT in the inferior, anteroseptal and septal regions and increases its sensitivity for the diagnosis of myocardial viability.     

Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results

The initial treatment of high-grade glioma often consists of surgery and radiation therapy. Chemotherapy is used in cases of recurrence or after incomplete surgery. Because of the many potential serious side-effects of chemotherapy, early tumour response evaluation is necessary to enable clinicians to adapt the treatment. However, response monitoring with computed tomography (CT) or magnetic resonance imaging (MRI) is often difficult. The aim of this study was to assess the value of repeated technetium-99m methoxyisobutylisonitrile (^99mTc-MIBI) single-photon emission computerised tomography (SPECT) for this purpose. Fifteen patients with malignant glioma were investigated with MIBI SPECT. Imaging was performed 1 h after the intravenous injection of 555 MBq of ^99mTc-MIBI, using a dedicated SPECT system (Tomomatic 564, Medimatic, Denmark). Overall, 57 investigations were performed. A MIBI uptake index was computed as the ratio of counts in the lesion to those in the contralateral region. Previous study had shown a cut-off value of 2.0 to be appropriate. SPECT indices were compared with neurological evaluation, CT or MRI. This assessment was performed every 4 months during and after the treatment. Six patients showed an increased MIBI index associated with clinical or radiological progression of disease during chemotherapy. After an initial response to therapy, three patients showed an increased MIBI index despite chemotherapy, demonstrating secondary resistance to therapy. Six patients showed a decreased MIBI index, demonstrating a good response to therapy. The first nine patients died shortly after the last SPECT scan (average duration of survival, 4 months). The therapeutic protocol was modified in six cases, but successfully so in only two. In some cases, tumour progression was diagnosed earlier with SPECT than on the basis of clinical or MRI signs. Early response or resistance to chemotherapy is detectable by^99mTc-MIBI SPECT. Therefore this functional imaging modality could be considered as a valuable tool to permit effective adaptation of the therapeutic regimen in patients treated for recurrent high-grade glioma.     

Evaluating benign and malignant musculoskeletal lesions with radionuclide angiography and SPECT using Tc-99m MIBI

PURPOSE: The purpose of this study was to evaluate the use of radionuclide angiography and single photon emission computed tomography (SPECT) using Tc-99m hexakis-2-methoxyisobutylisonitrile (Tc-99m MIBI) for analyzing musculoskeletal lesions. MATERIALS AND METHODS: Radionuclide angiography and SPECT using Tc-99m MIBI were performed in 36 patients with various soft tissue and bone pathologies (18 benign and 18 malignant lesions). The ratio of the counts of the lesion to that of the contralateral normal area was calculated from the region of interest drawn on the MIBI scan. The MIBI-uptake ratio was calculated using SPECT and the MIBI-perfusion index was calculated using radionuclide angiography. RESULTS: The MIBI-uptake ratio in malignant lesions (4.80 +/- 4.43) was significantly higher (P < 0.05) than that in benign lesions (1.83+/-2.48). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of the MIBI-uptake ratio for malignant lesions were 72%, 83%, 78%, 81%, and 75%, respectively. The MIBI-perfusion index in malignant lesions (17.68 +/- 21.19) was significantly higher (P < 0.05) than that in benign lesions (2.25 +/- 2.56). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of the MIBI-perfusion index for malignant lesions were 87%, 75%, 81%, 77%, and 86%, respectively. CONCLUSIONS: The MIBI-uptake ratio and MIBI-perfusion index using Tc-99m MIBI can yield important additional information with which to differentiate musculoskeletal lesions.     

99mTc-MIBI显像定位诊断甲状旁腺功能亢进的临床价值

目的：评价＾９９ｍＴｃ－ＭＩＢＩ显像在定位诊断早状旁腺功能亢进中的价值。材料和方法：３０例临床诊断或高度怀疑甲旁亢患者于颈部及上胸部行＾９９ｍＴｃ－ＭＩＢＩ显像,采用双时相法（１５ｍｉｎ即刻相及１２０ｍｉｎ延迟相）并加做＾９９ｍＴｃ－ＭＩＢＩ全身显像,同期做Ｂ超（３０例）和ＣＴ检查（１０例）。结果：与手术病理结果对照,＾９９ｍＴｃ－ＭＩＢＩ显像、Ｂ超和ＣＴ诊断准确性分别为８３．３％、６３．３％和７０％,对于正常位置、异位、术后复发,＾９９ｍＴｃ－ＭＩＢＩ显像阳性检出率均较Ｂ超、ＣＴ高。结论：＾９９ｍＴｃ－ＭＩＢＩ显像在定位诊断甲状旁腺功能亢进疾患具有较高临床价值,万其对异位和术后复发及确定有无三发性甲旁亢的敏感性优于Ｂ超、ＣＴ,可作为甲状旁腺功能亢进症术前定位诊断的主要手段。     

Evaluation of uptake and release of technetium-99m MIBI SPECT of pulmonary and mediastinal lesions

We evaluated the uptake and release of Tc-99m MIBI in 7 benign and 30 malignant pulmonary and mediastinal lesions. Of the 37 patients, 13 underwent surgery; malignant involvement was examined in 21 mediastinal lymph nodes. Tl-201 SPECT was also performed in 10 patients. Tc-99m MIBI SPECT studies were performed on transverse SPECT images acquired 30 minutes and 3 hours after intravenous injection of 600 MBq of Tc-99m MIBI with three gamma camera detectors (GCA-9300A). Regions of interest were set in the area of abnormal uptake of Tc-99m MIBI and in an area of normal tissue in the contralateral lung. The uptake ratio of the lesion in the contralateral normal lung was obtained on the early image (early ratio; ER) as well as the delayed image (delayed ratio; DR). The benign lesions showed significantly lower ER (1.6 ± 0.3) and DR (1.4 ± 0.4) than the malignant lesions (1.9 ± 0.5 and 1.8 ± 0.5, respectively; both p < 0.05). There was no significant difference in the retention index (RI), calculated as RI = (DR ? ER)/ER × 100. The DR obtained with Tl-201 SPECT images was significantly higher than that obtained with Tc-99m MIBI SPECT (p < 0.05). For the detection of mediastinal lymph node metastases, the early images showed sensitivity, specificity, and accuracy of 85.7%, 100%, and 95.2%, respectively, for the delayed images these values were 85.7%, 92.9%, and 90.5%, respectively. These results suggest that the uptake ratio of Tc-99m MIBI is a useful index in assessing benign or malignant pulmonary and mediastinal lesions.